Demographic characteristic of study population
| Variables | Control (n=203) | ACS (n=252) | SA (n=112) |
| Age (years) | 46.67±8.3 | 47.7±8.7 | 50.86±6.3*** |
| Gender (M/F) | 175/28 | 233/19 | 100/12 |
| Risk factors | |||
| Diabetes, n (%) | 23 (11.3) | 109 (43.2)*** | 51 (45.5)*** |
| Hypertension, n (%) | 22 (10.8) | 71 (28.1)*** | 45 (40.1)*** |
| Smoking, n (%) | 50 (24.6) | 124 (49.2)*** | 39 (34.8)* |
| BMI | 25.15±3.78 | 25.39±3.69 | 25.38±3.49 |
| WHR | 0.92±0.06 | 0.93±0.07 | 0.93±0.09 |
| Lipid levels (mmol/L) | |||
| TC | 5.03±0.010.25 | 4.32±1.05*** | 3.68±1.13*** |
| TG | 1.9±0.010.25 | 1.78±0.92 | 1.88±0.96 |
| HDL | 1.02±0.32 | 0.84±0.24*** | 0.76±0.23*** |
| LDL | 3.15±0.91 | 2.72±0.93*** | 2.1±1.02*** |
| FBS | 6.35±2.26 | 9.27±3.77*** | 7.72±4.97*** |
| Circulating T cells and cytokines | |||
| Th17 | 3.71±1.15 | 4.91±1.61*** | 4.56±1.91*** |
| Treg | 4.01±1.34 | 3.29±01.38*** | 3.18±01.25*** |
| IL17 (pg/mL) | 12.07±1.71 | 21.43±2.18** | 14.25±1.71* |
| Medications, n (%) | |||
| Beta-blockers | 4 (1.9) | 194 (76.9)*** | 82 (73.2)*** |
| ACE inhibitors | 2 (0.9) | 131 (51.9)*** | 19 (16.9)*** |
| Statin | 3 (1.4) | 229 (90.8)*** | 104 (92.8)*** |
| Aspirin (antiplatelet) | 3 (1.4) | 230 (91.2)*** | 101 (90.1)*** |
| Number of affected vessels, n (%) | |||
| 1 | 120 (47.6) | 27 (24.1) | |
| 2 | 49 (19.4) | 29 (25.8) | |
| 3 | 25 (9.9) | 42 (37.5) | |
The values are expressed as mean±SD or numbers (%). All the values were log transformed prior to analysis. A comparison was made between age and gender-matched controls and patients.
P value <0.05 was considered as significant. *P<0.05; **P<0.01; ***P<0.001.
ACS, acute coronary syndrome; BMI, body mass index; FBS, fasting blood sugar; HDL, high-density lipoprotein; IL, interleukin; LDL, low-density lipoprotein; SA, stable angina; TC, total cholesterol; TG, triglycerides; WHR, waist-hip ratio.